Edwards Lifesciences (EW) Scheduled to Post Earnings on Thursday

Edwards Lifesciences (NYSE:EW) will post its quarterly earnings results after the market closes on Thursday, April 25th. Analysts expect Edwards Lifesciences to post earnings of $0.64 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter last year, the company posted $0.64 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $87.24 on Thursday. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $52.51 billion, a price-to-earnings ratio of 37.93, a PEG ratio of 4.42 and a beta of 1.05. The firm’s 50 day moving average is $90.12 and its 200-day moving average is $78.14. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock worth $17,166,254 in the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in the business. Sanibel Captiva Trust Company Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at $592,000. Oarsman Capital Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $344,000. Harbour Investments Inc. raised its position in shares of Edwards Lifesciences by 14.9% in the fourth quarter. Harbour Investments Inc. now owns 3,632 shares of the medical research company’s stock valued at $277,000 after purchasing an additional 471 shares during the period. O Dell Group LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $34,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of Edwards Lifesciences by 1.3% during the 4th quarter. Public Employees Retirement System of Ohio now owns 364,608 shares of the medical research company’s stock worth $27,801,000 after buying an additional 4,752 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on EW. Citigroup lifted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Truist Financial boosted their price objective on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Oppenheimer raised their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $91.73.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.